Eli Lilly and Company (NYSE:LLY) Shares Bought by Voya Investment Management LLC

Voya Investment Management LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 29.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,421,038 shares of the company's stock after acquiring an additional 321,154 shares during the period. Eli Lilly and Company accounts for approximately 1.1% of Voya Investment Management LLC's investment portfolio, making the stock its 12th biggest position. Voya Investment Management LLC owned about 0.15% of Eli Lilly and Company worth $1,096,786,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of LLY. Dauntless Investment Group LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $408,000. Integrated Wealth Concepts LLC increased its position in Eli Lilly and Company by 5.4% during the fourth quarter. Integrated Wealth Concepts LLC now owns 29,438 shares of the company's stock worth $22,726,000 after purchasing an additional 1,519 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings in Eli Lilly and Company by 0.4% in the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 35,229 shares of the company's stock valued at $27,204,000 after purchasing an additional 137 shares during the last quarter. Burling Wealth Partners LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $6,306,000. Finally, J. Stern & Co. LLP increased its holdings in shares of Eli Lilly and Company by 23.9% during the 4th quarter. J. Stern & Co. LLP now owns 3,485 shares of the company's stock worth $2,690,000 after buying an additional 673 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent analyst reports. Guggenheim decreased their price objective on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Wells Fargo & Company upped their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday. They set an "overweight" rating and a $975.00 price objective for the company. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a research report on Friday, January 17th. Finally, Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Two analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $1,017.00.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Up 2.9 %

Shares of LLY stock traded up $25.21 on Friday, reaching $884.94. 3,395,903 shares of the stock were exchanged, compared to its average volume of 3,439,006. The company has a market capitalization of $839.07 billion, a price-to-earnings ratio of 75.57, a PEG ratio of 1.40 and a beta of 0.51. The business's 50 day moving average price is $827.69 and its 200 day moving average price is $818.61. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.